Beijing Bio-Targeting Therapeutics

Beijing Bio-Targeting Therapeutics is a clinical-stage biotechnology company based in China, specializing in the development of next-generation targeted therapies for oncology. The company leverages a proprietary drug delivery platform to design high-precision Antibody-Drug Conjugates (ADCs) and small molecule inhibitors aimed at overcoming resistance in solid tumors. Their pipeline features candidates targeting well-validated pathways such as EGFR and HER2, with a focus on improving the therapeutic window and safety profiles of traditional treatments. By integrating advanced conjugation technologies with novel linker-payload systems, Beijing Bio-Targeting Therapeutics aims to provide more effective options for patients with refractory cancers.